Financial Tear Sheet

Corporate Profile

LabCorp (NYSE: LH), an S&P 500 company, is a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostic solutions, brings innovative medicines to patients faster and uses technology to improve the delivery of care. LabCorp reported net revenues of over $10 billion in 2017. To learn more about LabCorp, visit www.labcorp.com,and to learn more about Covance Drug Development, visit www.covance.com.

More Information

Primary IR Contact
Scott Frommer
Vice President, Investor Relations
Laboratory Corporation of America Holdings
Phone: 336-436-5076
Fax: 336-436-1569
E-mail: investor@labcorp.com

Stock Performance
LH (Common)
ExchangeNYSE (US Dollar)
Price$187.31
Change (%) Stock is Up 1.40 (0.75%)
Volume550,416
52 Week Low$140.47
Market Cap$19,161,813,000
Rolling EPS12.13
PE Ratio15.4419
Shares Outstanding102,300,000
Data as of 06/19/18 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.
Stock chart for: LH.  Currently trading at $187.31 with a 52 week high of $190.35 and a 52 week low of $140.47.
Recent News & Events
06/11/18 - 8:31 a.m.
LabCorp Expands Drug Development Solutions with Acquisition of Sciformix
06/05/18 - 5:05 p.m.
LabCorp is Scheduled to Present at the 38th Annual William Blair Growth Stock Conference
06/01/18 - 8:00 a.m.
LabCorp and Unilabs Collaborate to Expand Global Reach of Precision Medicine Capabilities to Serve Patients, Physicians and Pharma
There are currently no events scheduled.
Analyst Estimates / Ratings
Mean Recommendation: 1.9

Buy
SellStrong Buy
Unable to fulfill request.
SEC Filings
Filing DateForm
06/12/188-K XBRL SEC Filing Unavailable
06/11/188-K XBRL SEC Filing Unavailable
06/08/184 XBRL SEC Filing Unavailable
06/06/184 XBRL SEC Filing Unavailable
Corporate Governance
David P.  KingChairman and Chief Executive Officer
Glenn A. EisenbergExecutive Vice President and Chief Financial Officer
Gary M. HuffChief Executive Officer, LabCorp Diagnostics
John D.  RatliffChief Executive Officer, Covance Drug Development
Lance V. BerberianSenior Vice President and Chief Information Officer
Edward T. DodsonSenior Vice President and Chief Accounting Officer
F. Samuel Eberts IIISenior Vice President, Chief Legal Officer and Secretary
Lisa J. UthgenanntChief Human Resources Officer
Brian J. CaveneyChief Medical Officer
Ownership Summary
Shareholders
 HoldersValue ($MM)% O/SShares
Institution1,07215,782.0695.697,479,605
Mutual Fund1,3908,255.6847.648,528,179
Insider *1768.110.4394,967
*Insider values reflect direct beneficial ownership.
Top Holders
 Shares Held% O/SShare ChangeFiling Date
The Vanguard Group, Inc.10,694,47410.5172,07803/31/18
BlackRock Institutional Trust Company, N.A.5,815,5605.761,92503/31/18
Boston Partners5,673,7675.6409,74203/31/18
State Street Global Advisors (US)4,134,8594.1-238,45303/31/18
Nordea Funds Oy2,170,4642.1-44,23503/31/18
Glenview Capital Management, LLC1,856,8321.8-813,59403/31/18
Iridian Asset Management LLC1,690,9211.772,69503/31/18
Dimensional Fund Advisors, L.P.1,426,9131.4-53703/31/18
JP Morgan Asset Management1,299,7741.3-70,46203/31/18
Geode Capital Management, L.L.C.1,214,7591.297,33003/31/18